CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Available-for-sale Securities, Gross Unrealized Loss
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Available-for-sale Securities, Gross Unrealized Loss of $0 for the 12-month period ending 2013-12-28, per its 10-Q filed 2013-10-30.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss · last filed 2014-02-25
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. available-for-sale securities, gross unrealized loss for the quarter ending 2013-12-28 was $0.00.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. available-for-sale securities, gross unrealized loss for fiscal 2012 was $0.00.
| Period end | Available-for-sale Securities, Gross Unrealized Loss 3 month | Available-for-sale Securities, Gross Unrealized Loss 9 month | Available-for-sale Securities, Gross Unrealized Loss 12 month |
|---|---|---|---|
| 2013-12-28 | $0.00 derived: 10-Q 12 month − 10-Q 9 month · filed 2013-10-30 | $0.00 10-Q · filed 2013-10-30 | |
| 2013-09-28 | $0.00 10-Q · filed 2013-10-30 | ||
| 2012-12-29 | $0.00 10-K · filed 2014-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |